The inhibition of astrocytic D-serine production and release in a mouse model of Alzheimer’s disease improves synaptic function [93], raising the possibility that targeting the astrocytic production of D-serine, or ASCT1 mediated D-serine release would represent a novel Alzheimer’s disease therapy, which is divergent from the current anti-amyloid strategies [94]. Here, SLC1A4 is linked to early-onset autosomal dominant Alzheimer disease.